FDA Approval Alert: The Need-to-Know | Amivantamab/Chemo in EGFR Exon 20+ NSCLC

In March 2024, the FDA approved amivantamab-vmjw in combination with carboplatin and pemetrexed as frontline therapy for patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

Data from the phase 3 PAPILLON trial support the FDA approval of amivantamab plus chemotherapy for patients with metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations.
FDA Approves Amivantamab/Chemo in EGFR Exon 20+ NSCLC
Article
Mar 1, 2024 8:04 PM
Data from the phase 3 PAPILLON trial support the FDA approval of amivantamab plus chemotherapy for patients with metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations.